(Q46084072)

19 December 2017

title

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy (English)

1 reference

19 December 2017

main subject

dasatinib monohydrate

1 reference

1 reference

1

1 reference

19 December 2017

Auvo Rauhala

14

1 reference

19 December 2017

Kimmo Porkka

object named as

K Porkka

20

0 references

François Guilhot

object named as

F Guilhot

6

0 references

Jane L. Liesveld

11

object named as

J Liesveld

1 reference

19 December 2017

author name string

M Ekblom

2

1 reference

19 December 2017

T P Arstila

3

1 reference

19 December 2017

I Dybedal

4

1 reference

19 December 2017

P K Epling-Burnette

5

1 reference

19 December 2017

H Hjorth-Hansen

7

1 reference

19 December 2017

M Höglund

8

1 reference

19 December 2017

P Kovanen

9

1 reference

19 December 2017

T Laurinolli

10

1 reference

19 December 2017

R Paquette

12

1 reference

19 December 2017

J Pinilla-Ibarz

13

1 reference

19 December 2017

N Shah

15

1 reference

19 December 2017

B Simonsson

16

1 reference

19 December 2017

M Sinisalo

17

1 reference

19 December 2017

J L Steegmann

18

1 reference

19 December 2017

L Stenke

19

1 reference

19 December 2017

publication date

19 March 2009

1 reference

19 December 2017

published in

Leukemia

1 reference

19 December 2017

volume

23

1 reference

19 December 2017

issue

8

1 reference

19 December 2017

page(s)

1398-1405

1 reference

19 December 2017

Chronic myeloid leukaemia

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

Profound inhibition of antigen-specific T-cell effector functions by dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

Dasatinib suppresses in vitro natural killer cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

Characteristics of human large granular lymphocytes and relationship to natural killer and K cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

inferred from DOI database lookup

7 January 2021

based on heuristic

Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

inferred from DOI database lookup

7 January 2021

based on heuristic

Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.46

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/LEU.2009.46

1 reference

19 December 2017

Dimensions Publication ID

1012226579

0 references

1 reference

19 December 2017